PMID- 30553401
OWN - NLM
STAT- MEDLINE
DCOM- 20200226
LR  - 20200226
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Linking)
VI  - 140
DP  - 2019 Jan
TI  - The omega-3 index in patients with heart failure: A prospective cohort study.
PG  - 34-41
LID - S0952-3278(18)30195-9 [pii]
LID - 10.1016/j.plefa.2018.11.012 [doi]
AB  - BACKGROUND: Epidemiologic studies on the omega-3 fatty acids eicosapentaenoic 
      acid (EPA) and docosahexaenoic acid (DHA) in heart failure are scarce, while one 
      large intervention trial demonstrated a modest benefit. METHODS: This is a 
      secondary analysis from the Interdisciplinary Network Heart Failure (INH) 
      program. Patients hospitalized for systolic heart failure were enrolled and 
      followed for 36 months. At baseline, whole blood samples from 899 patients were 
      analyzed for fatty acid composition using a standardized analytical procedure 
      (HS-Omega-3 Index(R), O3-I). Associations of the O3-I with markers of heart failure 
      severity, clinical characteristics, biomarkers, and mortality were analyzed. 
      RESULTS: The mean O3-I was 3.7 +/- 1.0%. Patient mean age was 68 +/- 12 years (72% 
      male, 43% in New York Heart Association (NYHA) class III or IV, mean LVEF 
      30 +/- 8%). During follow-up 258 patients (28.7%) died. After adjustment for 
      potential confounders, the O3-I showed weak associations with uncured malignancy, 
      end-systolic diameter of the left atrium, left ventricular end-diastolic and 
      end-systolic diameters, and blood lipids and other laboratory parameters (all 
      p < 0.05), but not with NYHA class, left ventricular ejection fraction, and the 
      underlying cause of heart failure. The O3-I did not predict the 3-year mortality 
      risk. CONCLUSIONS: Our results show a marked depletion of omega-3 fatty acids in 
      patients hospitalized for decompensated heart failure (suggested target range 
      8-11%). Although the O3-I was associated with a panel of established risk 
      indicators in heart failure, it did not predict mortality risk. CLINICAL TRIAL 
      REGISTRATION: www.controlled-trials.com; ISRCTN23325295.
CI  - Copyright (c) 2018. Published by Elsevier Ltd.
FAU - Berliner, Dominik
AU  - Berliner D
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Hannover Medical School (MHH), Dept. of Cardiology and Angiology, 
      Hannover, Germany.
FAU - Mattern, Sarah
AU  - Mattern S
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany.
FAU - Wellige, Mareike
AU  - Wellige M
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany.
FAU - Malsch, Carolin
AU  - Malsch C
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Institute of Clinical Epidemiology and Biometry, University of Wurzburg, 
      Germany.
FAU - Guder, Gulmisal
AU  - Guder G
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Dept. of Internal Medicine I - Cardiology, University Hospital Wurzburg, 
      Germany.
FAU - Brenner, Susanne
AU  - Brenner S
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Dept. of Internal Medicine I - Cardiology, University Hospital Wurzburg, 
      Germany.
FAU - Morbach, Caroline
AU  - Morbach C
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Dept. of Internal Medicine I - Cardiology, University Hospital Wurzburg, 
      Germany.
FAU - Deubner, Nikolas
AU  - Deubner N
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Kerckhoff Clinic, Centre for Heart, Thoracic and Rheumatic Diseases, Bad 
      Nauheim, Germany.
FAU - Breunig, Margret
AU  - Breunig M
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Dept. of Internal Medicine I - Cardiology, University Hospital Wurzburg, 
      Germany.
FAU - Kiefl, Rosemarie
AU  - Kiefl R
AD  - Omegametrix, Martinsried, Germany.
FAU - Angermann, Christiane E
AU  - Angermann CE
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Dept. of Internal Medicine I - Cardiology, University Hospital Wurzburg, 
      Germany.
FAU - Ertl, Georg
AU  - Ertl G
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Dept. of Internal Medicine I - Cardiology, University Hospital Wurzburg, 
      Germany.
FAU - von Schacky, Clemens
AU  - von Schacky C
AD  - Omegametrix, Martinsried, Germany; Preventive Cardiology, Medical Clinic I, 
      Ludwig Maximilians-University, Munich, Germany.
FAU - Stork, Stefan
AU  - Stork S
AD  - Comprehensive Heart Failure Center, University and University Hospital Wurzburg, 
      Germany; Dept. of Internal Medicine I - Cardiology, University Hospital Wurzburg, 
      Germany. Electronic address: Stoerk_S@ukw.de.
LA  - eng
SI  - ISRCTN/ISRCTN23325295
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20181128
PL  - Scotland
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
RN  - 0 (Biomarkers)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - AAN7QOV9EA (Eicosapentaenoic Acid)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Docosahexaenoic Acids/*blood
MH  - Eicosapentaenoic Acid/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/mortality
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Ventricular Dysfunction, Left/physiopathology
OTO - NOTNLM
OT  - Biomarker
OT  - Fatty acids
OT  - Heart failure
OT  - Omega-3 index
OT  - Prognosis
EDAT- 2018/12/17 06:00
MHDA- 2020/02/27 06:00
CRDT- 2018/12/17 06:00
PHST- 2018/09/13 00:00 [received]
PHST- 2018/11/26 00:00 [revised]
PHST- 2018/11/27 00:00 [accepted]
PHST- 2018/12/17 06:00 [entrez]
PHST- 2018/12/17 06:00 [pubmed]
PHST- 2020/02/27 06:00 [medline]
AID - S0952-3278(18)30195-9 [pii]
AID - 10.1016/j.plefa.2018.11.012 [doi]
PST - ppublish
SO  - Prostaglandins Leukot Essent Fatty Acids. 2019 Jan;140:34-41. doi: 
      10.1016/j.plefa.2018.11.012. Epub 2018 Nov 28.